

Attorney Docket No.: 4228.410 US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Byskov et al.

Application No.: 10/058,436

Group Art Unit: 1651

Filed: January 23, 2002

Examiner: S. Saucier

Confirmation No: 5453

For: Regulation of Meiosis

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

In response to the Restriction Requirement dated July 2, 2003, Applicants wish to elect wish to elect with traverse, the species recited in claim 21, 4,4-dimethyl-5 α -cholesta-8,14,24-triene-3 β -ol.

The Examiner is invited to contact the undersigned by telephone at (914) 712-0093 if there are questions or comments regarding this application or response.

Respectfully submitted,

Date: 7/25/03



Cheryl H. Agris, Reg. No. 34,086
Counsel for
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540